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Human health hazard assessment programs generally provide a sin-
gle estimate (e.g., a toxicity value such as a reference dose (RfD) (United
States Environmental Protection Agency, 1993) or an acceptable daily
intake (European Food Safety Authority, 2013) as a ﬁnal output. These
toxicity values are then employed to derive point estimates of human
health risks associated with environmental exposures and are regularly
used by risk managers in regulatory decision-making for setting stan-
dards, determining emission controls, and mitigating exposures to pol-
lutants.Methodologies used to derive point estimates for toxicity values
vary, and many rely on upper bound assumptions. While scientiﬁc con-
siderations theoretically support a range of values, in practice, typically
only a single toxicity value is communicated. In addition, there is gener-
ally limited information provided on the components of toxicity value
determinations, in particular the assumptions and uncertainty factors
embedded in such point estimates, and the effects and impacts these
have on toxicity values and the risk estimates resulting from their use.
Without an improved approach to communication, it is difﬁcult to
fully convey the plausible range of toxicity values embodied in these
point estimates. In addition, using point estimates without describing
the inherent uncertainty provides a false sense of accuracy. Consequent-
ly, the conﬁdence in the scientiﬁc basis for regulatory decision-making
can suffer, and risk-management decisions may be unnecessarily
constrained or inappropriately directed.
Users of toxicity characterizations, such as those developed as part of
the U.S. Environmental Protection Agency (EPA) Integrated Risk Infor-
mation System (IRIS) program, the Agency for Toxic Substances and
Disease Registry (ATSDR)'s Toxicological Proﬁles and other similar haz-
ard databases, should be able to objectively determine the accuracy and
precision of reported toxicity values. Furthermore, users should be pro-
vided a clear and transparent description of the impacts of the assump-
tions made, and/or incorporating alternative plausible assumptions or
other information, on the resulting toxicity values. Currently, however,
such transparency is often lacking, and impacts are not always readily
apparent even to expert risk assessors.
In many cases, it is challenging for risk assessors, risk managers, and
stakeholders to understand and visualize all of the assumptions, uncer-
tainties, and policy decisions embedded in a hazard characterization.
For example, some toxicity assessment approaches focus on developing
a toxicity value whichwill be protective of all populations in all circum-
stances, while others derive toxicity values that strive to be predictive of
toxicity in humans. If the toxicity value is intended to be protective, the
extent of health protectiveness of the toxicity value should bedescribed.
If the value is intended to be predictive, the overall conﬁdence in the
value should reﬂect the accuracy of its derivation. The assumptions
and uncertainties embedded in protective and predictive toxicity values
can differ substantially. It would be helpful, therefore, if health and risk
assessments clearly and systematically identify, evaluate, and transpar-
ently describe the major uncertainties. When provided with a clear un-
derstanding of the uncertainties in these assessments, users will be
better able to understand an agency's justiﬁcation for the overall conﬁ-
dence with which a toxicity value may be used, and the impact of as-
sumptions and uncertainties on risk management options.
There are many approaches that can be taken to improve risk com-
munication (Lundgren and McMakin, 2013). Speciﬁcally in regards to
the presentation of uncertainty, in 1989, the National Academy of Sci-
ences (NAS) suggested that it was important to communicate “someindication of the level of conﬁdence of the estimates and the signiﬁcance
of scientiﬁc uncertainty” (National Research Council, 1989). Indeed
there is a great deal of theory and evidence behind the need to better
quantify uncertainty to avoid decisions that may even increase, rather
than decrease, risk (Gray and Cohen, 2012; Morgan et al., 1992;
National Research Council, 2009; Nichols and Zeckhauser, 1988).
Some research has suggested that the public may view expressions of
uncertainty by risk assessors as demonstrating either honesty or incom-
petence (Johnson and Slovic, 1995). However, more recent research has
noted that distrust will increase when uncertainties are not included in
the discussion of the assessments (Frewer and Salter, 2012).
Many within the risk assessment community have stressed the im-
portance of making the process of toxicity value development more ac-
cessible and transparent (Simon, 2011). Understanding how and why
assessments differ helps to illuminate the sources of uncertainty in a
particular assessment and the impact of judgments and assumptions
on the ﬁnal toxicity value. Appropriately designed visual aids have
been suggested as desirable tools as they can help to improve risk com-
munication. Visual aids have been effectively used to communicate risks
associated with different medical treatments, screenings, and lifestyles
(Waters et al., 2007; Zikmund-Fisher et al., 2008). These visual aids
can also increase appropriate risk-avoidance behaviors, promote
healthy behaviors, and reduce errors induced by anecdotal narratives
(Cox et al., 2010; Fagerlin et al., 2005; Schirillo and Stone, 2005). More-
over, visual representations of risk information are more readily under-
stood and retained, and require less viewing time than the same
information presented numerically (Feldman-Stewart et al., 2007;
Gaissmeier et al., 2012; Goodyear-Smith et al., 2008).
On November 6–7, 2013 the American Chemistry Council's Center
for Advancing Risk Assessment Science and Policy hosted an invited
participant workshop with the principle objective of exploring ap-
proaches to improving methods for presenting uncertainty and risk in-
formation in federal chemical hazard assessment programs. Participants
included more than 60 experts in toxicology, risk assessment, risk com-
munication, exposure assessment, and hazard characterization drawn
from academia, government and industry, and non-governmental orga-
nizations; the workshop agenda and list of participants are provided in
the Supplementary Material. Workshop participants developed ap-
proaches for best practices for presenting hazard characterization sum-
maries and tables. While IRIS was used as a case study, the approaches
developed by workshop participants are also applicable to similar data-
bases, including the ATSDR minimal risk levels (MRLs) and the
European Chemicals Agency derived no-effect levels, and could also be
adopted or adapted by other agencies and programs. Following the
workshop, guided by the participants' discussions, the best practice ap-
proaches were reﬁned, examples were further elaborated, and visual
aids were ﬁne-tuned. In addition, to receive further feedback, a few of
these proposed approaches were presented at a workshop during the
annual meeting of the Society of Toxicology (Farland, 2015; Grant,
2015; Kirman, 2015). This paper describes the outcome of those ef-
forts— several recommended paths forward for improving communica-
tion of uncertainties in the underpinnings of toxicity values.
2. Methods and approaches
We describe four approaches (1–4 below) aimed at improving the
presentation and facilitating the communication of uncertainty in IRIS
summaries, IRIS Toxicological Reviews, and other similar assessments.
4 Groups included in ITER are: ATSDR; Health Canada; International Agency for Re-
search on Cancer (IARC), NSF International; RIVM; TCEQ; EPA; ITER Peer Review; and In-
dependent Peer Review Value.
Table 1
A comparison table to portray toxicity values derived by different organizations.
Example of risk values comparison table: carbon tetrachloride
Category (section) U.S. EPA ATSDR IARC RIVM
Chronic oral assessment (I.A.) Type RfD Chronic MRL – TDI
Value 0.004 mg/kg-day Qualitative – 0.004 mg/kg-day
Last revised 03/31/2010 2005 – 2000
Chronic inhalation assessment (I.B.) Type RfC Chronic MRL – TCA
Value 1E−1 mg/m3 1.9E–1 mg/m3
(0.03 ppm)
– 6E−2 mg/m3
(60 μg/m3)
Last revised 03/31/2010 2005 – 2000
Oral carcinogenicity assessment (II.) Type OSF – – CR (oral)
Value 0.007 mg/kg-day
(RSD = 1.4E−1 mg/kg-day)
Qualitative Qualitative Qualitative
Last revised 03/31/2010 2005 1999 2000
Inhalation carcinogenicity assessment (II.) Type IUR – – CR (inhal)
Value 6E−6 per (μg/m3)
(RSC = 1.7E−3 μg/m3)
Qualitative Qualitative Qualitative
Last revised 03/31/2010 2005 1999 2000
Note: If a valuewasderived it is considered quantitative; if no valuewasderived, but the datawere evaluated, the status it is designated as “qualitative”; “–” signiﬁes that no evaluationwas
reported. OSF, oral slope factor; RSD, risk speciﬁc dose; IUR, inhalation unit risk; RSC, risk speciﬁc concentration; TDI, tolerable daily intake; TCA, tolerable concentration in air; CR, cancer
risk.
Legend: A summary table of toxicity value information on carbon tetrachloride from the ITER database and the IRIS Carbon Tetrachloride Assessment. This example illustrates themanner
inwhich tabular presentation can facilitate comparison of toxicity values derived by different organizations (Agency for Toxic Substances and Disease Registry, 2005; International Agency
for Research on Cancer, 1999; United States Environmental Protection Agency, 2010b; United States National Library of Medicine, 2014).
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be provided on a web page as further educational information, is also
described. The approaches are:
1. Comparing available peer reviewed toxicity values for a speciﬁc
chemical per the criteria of the International Toxicity Estimates for
Risk (ITER) database;
2. Deconstructing the toxicity value to enhance transparency and im-
prove communication of the overall conﬁdence in the value;
3. Presenting toxicological information visually in the context of alter-
native points of departure (PODs), toxicity values, and exposure
levels;
4. Evaluation of the uncertainty in individual elements of the hazard
characterization; and,
5. Visual depiction of the toxicity value uncertainty range in association
with a probability distribution of exposures.
Each of these approaches is described in this section. The ﬁve ap-
proaches are designed to be distinct and can be used individually or in
conjunction with other approaches.
Visual aids tend to bemost effectivewhen the contextual relationships
in the data are depicted clearly. A successful visual presentation has well-
deﬁned elements that accurately and clearly represent the relevant infor-
mation. Because individuals possess a range of abilities in interpreting and
understanding visual information, in order to convey complex informa-
tion to awide array of audiences, multiple visual aids containing different
levels and amounts of information are desirable. There needs to be an ap-
propriateﬁt between the visual aids andpeople's skills, processes, and en-
vironments (Cokely and Kelley, 2009). For example, risk assessors, risk
managers, and the general public differ in their ability to recognize and
contextualize the relationships of the elements and parameters embed-
ded in hazard and risk assessments. Tailoring visual aids to the speciﬁc au-
dience will enhance the ability of these aids to confer understanding and
will improve the utility of these aids.
2.1. Approach 1: identiﬁcation and comparison of peer reviewed toxicity
values for an individual chemical
All toxicological assessments involve application of professional
judgments, assumptions, and science policies, and it is not uncommon
for different experts and independent regulatory bodies to reach dis-
similar conclusions when evaluating similar datasets. Understanding
how and why assessments differ helps to illuminate the sources ofuncertainty in a particular assessment and the impact of judgments
and assumptions on the ﬁnal toxicity value.
In some cases differences can stem from the fact that different agen-
cies derived their toxicity values using different (e.g., newer versus
older) scientiﬁc studies, information, or methods. In other cases, assess-
ments may be based on the same contemporary information but utilize
the data differently, apply different science policies, or make different
professional judgments. In order to communicate uncertainty, we pro-
pose an approach that provides a side-by-side comparison and a synop-
sis of the key similarities and differences among the different values.
One way to use the approach of side-by-side comparisons of peer-
reviewed toxicity values would be to initiate a de novo search for values
across agencies. However, amore efﬁcientmethodwould be to examine
the existing ITER database. ITER is a free Internet database, accessible on
the National Library of Medicine's website (United States National Li-
brary of Medicine, 2014), which provides human health toxicity values
and cancer classiﬁcations for over 680 chemicals of environmental con-
cern from multiple organizations worldwide.4 ITER presents toxicity
values from various authoritative organizations (including links to
each) in a tabular format and a synopsis explaining differences in the
toxicity values. Tables and synopses are readily downloadable and are
open source with no restrictions for use. A toxicity value needs to
have been formally peer reviewed and used by more than one group
to justify incorporation into the ITER database (Toxicology Excellence
For Risk Assessment, 2010).
An example of side-by-side comparison across toxicity values from
different organizations is shown in Tables 1 and 2; toxicity values
downloaded from ITER for carbon tetrachloride are used for this exam-
ple. In these example tables, the IRIS summary table format, which cur-
rently includes information solely on EPA's own toxicity values, has
beenmodiﬁed to also provide information from ITER sources. The com-
posite uncertainty value is presented in Table 2, as is currently done in
IRIS summaries, and in addition, each of the speciﬁc uncertainty factor
values applied by each organization is presented to enable direct com-
parison. Alongwith suchmodiﬁed tables, it is recommended that an as-
sessment would include a narrative discussion of the key differences
among the toxicity values derived by various organizations, with a
Table 2
Reference dose (RfD) comparison table.
Example of risk values comparison table: carbon tetrachloride
Agency Critical effect Point of departure UF Chronic value Date
U.S. Elevated serum SDH BMDL2X-ADJ: 1000 RfD = 0.004 mg/kg-day 2010
EPA activity 3.9 mg/kg-day UFH = 10
Subchronic oral rat study UFA = 10
UFS = 3
(Bruckner et al., 1986) UFD = 3
ATSDR – – – Qualitative evaluation only, did not derive a chronic MRL 2005
RIVM Liver NOAEL = 1 mg/kg-day 300 TDI = 0.004 mg/kg-day 2000
UFH = 10
Subchronic oral rat study UFA = 10
UFS = 3
Multiple studies UFD = NA
Note: SDH, sorbitol dehydrogenase.
Legend: A summary table comparing the toxicity values and the different adjustment factor values employed by various organizations. This table was created using data from the IRIS
Carbon Tetrachloride Assessment oral non-cancer IRIS summary and ITER (United States Environmental Protection Agency, 2010b; United States National Library of Medicine, 2014).
In an IRIS summary document a table like this could be presented in the section that begins the discussion of the oral non-cancer toxicity values. Similar tables could be created for
each endpoint in the hazard assessment (e.g., inhalation non-cancer value, oral cancer value, inhalation cancer value).
Table 3
Noncancer toxicity assessment elements.
Element Description for high conﬁdence*
Database
completeness
Database included investigations of a comprehensive array of
noncancer toxicity endpoints, established from studies of
chronic duration in various mammalian species (refer to
United States Environmental Protection Agency, 1994).
Systematic review A systematic approach was used to identify studies, evaluate
their quality and integrate them. This approach incorporates a
weight of evidence framework, as it uses objective
pre-deﬁned criteria for determining study relevance and
study quality coupled to an explicit evaluative framework to
provide a systematic approach for integrating different kinds
of scientiﬁc evidence for assessing the validity of a causal
hypothesis.
Key study quality The key study(ies) are well-conducted and can be used
without restrictions.
Critical effect The database is sufﬁcient to identify the effect occurring at
early time points (i.e. critical effect).This should protect
against all other adverse effects. MOA information, if
available, helps to determine if the earliest critical effect has
been identiﬁed.
Relevance of
critical effect
The critical effect is known to be related to human ﬁndings. If
only animal studies are available, MOA information, if
available, helps to determine if the critical effect is relevant to
humans.
Point of departure
(POD)
Dose–response is well understood and NOAEL and LOAEL are
identiﬁed. Ideally, BMC/BMD modeling was performed with
small differences between BMD and BMDL.
Human equivalent
POD
Human data are available or human equivalent
dose/concentration is known from PBPK or similar model.
Sensitive
populations
Human data on sensitive subpopulations are available or
PBPK or similar model is available to account for
toxicokinetic/toxicodynamic differences between general and
sensitive populations.
Conﬁdence scoring for each element is explained in more detail in the supplemental
materials.
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explanatory narrative should be commensurate with the level of differ-
ences seen. Topromote consistency across assessments,we recommend
having clearly developed criteria to describewhat should be included in
the narrative; for example, the basis for a qualitative evaluation, under-
lying input for derivations, and description of the uncertainty factors.
2.2. Approach 2: deconstructing toxicity assessments
The two main components in a toxicity characterization are hazard
identiﬁcation and dose–response assessment, and within each of these
components there are multiple steps or considerations. In this section,
themajor steps used to develop toxicity valueswill be referred to as “el-
ements.” Table 3 shows a typical example of the elements used when
deriving toxicity values, based on an approach used by the Texas Com-
mission on Environmental Quality (TCEQ) (Texas Commission on
Environmental Quality, 2012).
The following analytical approach is provided as an example of the
steps used to derive toxicity values for chemicals and to evaluate toxic-
ity values derived by others:
1. Review essential toxicity data using a systematic review andweight-
of-evidence/evidence integration process, including evaluation of
physical/chemical properties.
2. Evaluate the study quality of each key study and select the most ap-
propriate key studies.
3. Conduct mode of action (MOA) analyses and determinewhether the
critical effect is relevant to humans.
4. Choose the appropriate dose metric considering toxicokinetics and
MOA.
5. Determine the POD for each key study.
6. Conduct appropriate dosimetric modeling such as duration and
animal-to-human adjustments, as needed.
7. Select critical effect, based on human equivalent exposure after con-
sidering each key study.
8. Extrapolate from the adjusted POD to lower exposures based on
MOA analysis. For chemicals with a threshold MOA, apply appropri-
ate uncertainty factors. For chemicals with a non-threshold MOA,
consider low-dose extrapolation.
9. Conduct a peer review of the derivation of toxicity values including a
validation check, and compare the value to other organizations.
At the present time, IRIS summaries provide qualitative conﬁdence
rankings of low, medium, and high for database completeness and crit-
ical study quality when conducting non-cancer assessments. IRIS also
evaluates overall conﬁdence in the non-cancer toxicity values, with da-
tabase completeness taking precedence over study quality (UnitedStates Environmental Protection Agency, 1994). No conﬁdence evalua-
tion is provided for cancer assessments conducted by IRIS.
Rather than providing an overall assessment of uncertainty and con-
ﬁdence, we recommend deconstructing the toxicity assessment into its
elements and providing information on conﬁdence and uncertainty for
each element. Some of the major elements identiﬁed in this paper
were previously grouped into the overall evaluation of critical study
quality (e.g., relevance of animal studies to humans and demonstration
of dose–response relationships) by the IRIS program (United States En-
vironmental Protection Agency, 2002). In our view, transparency and
communication will be enhanced through a systematic, deconstructed
approach to characterizing the level of conﬁdence in each element sep-
arately. This information allows the user of the value to better
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deriving the toxicity value. A validation check, although not part of the
process for deriving a toxicity characterization, can also help to commu-
nicate and conﬁrm the accuracy and precision of the toxicity value (see
step 9 above).
The inclusion of these elements in an assessment summary, such as
those published by IRIS and other agencies, will enhance risk communi-
cation to stakeholders, including risk managers and decision-makers.
For the purpose of this section, we give equal weight to each major ele-
ment. However, based on the speciﬁc analysis and scenario(s) of con-
cern, more weight could be given to certain elements that are
particularly important to the derivation of a speciﬁc toxicity value.
2.2.1. Conﬁdence, accuracy and precision
As used in this section, the conﬁdence placed in any toxicity charac-
terization is inversely related to the degree of uncertainty in one or
more of the underlying analyses. Different types of risk management
decisions can be supported with different levels of conﬁdence/uncer-
tainty. The type of risk management decision inﬂuencing a speciﬁc
problem formulation will generally dictate the acceptable degree of un-
certainty. For example the identiﬁcation of a putative hazard of a chem-
ical using structural analogs and prediction modeling to inform further
testing decisions or for priority setting purposeswould tolerate a higher
degree of uncertainty (e.g., “may present an unreasonable risk of injury
to human health or the environment” under section 5(e) of the Toxic
Substances Control Act (TSCA)) in comparison to the conﬁdence re-
quired to underpin a regulatory action to implement costly risk man-
agement measures or an outright ban of the chemical substance
(e.g., “presents or will present an unreasonable risk of injury to health
or environment” under section 5(f) of TSCA).
A risk manager may have high conﬁdence in a decision if the scien-
tiﬁc uncertainties in the various analyses are low, and, correspondingly,
low conﬁdence in a decision if the scientiﬁc uncertainties are high.Table 4
Cancer toxicity assessment elements.
Element Description for high conﬁdence*
Carcinogenic
potential
Using a weight of evidence approach, and knowledge of MOA,
adequate data exists to classify the chemical into EPA/IARC
categories (e.g., not carcinogenic, possibly carcinogenic,
known carcinogen, etc.).
Systematic review A systematic approach was used to identify studies, evaluate
their quality and integrate them. This approach incorporates a
weight of evidence framework, as it uses objective
pre-deﬁned criteria for determining study relevance and
study quality coupled to an explicit evaluative framework to
provide a systematic approach for integrating different kinds
of scientiﬁc evidence for assessing the validity of a causal
hypothesis.
Key study quality The key study(ies) are well-conducted and can be used
without restrictions.
Relevance of
critical effect
The tumor type/site is known to be related (or may be
related) to human ﬁndings. If only animal studies are
available, MOA information, if available, helps to determine if
the critical effect is relevant to humans.
Point of departure Dose–response is well understood. Ideally, BMC/BMD
modeling was performed with small differences between
BMD and BMDL.
Human equivalent
POD
Human data are available or human equivalent
dose/concentration is known from PBPK or similar model.
Low dose
extrapolation
A biologically based model or PBPK model is available and
MOA understanding leads to extrapolation to lower doses
with conﬁdence.
Sensitive
populations
Human data on sensitive subpopulations are available or
PBPK or similar model available to account for
toxicokinetic/toxicodynamic differences between general and
sensitive populations. If the MOA is mutagenic, then
age-dependent adjustment factors were applied.
Conﬁdence scoring for each element is explained in more detail in the supplemental
materials.When conﬁdence in a major element is low (i.e., uncertainty is high),
risk assessors tend to use conservative assumptions and defaults to en-
sure that health risks are not underestimated (United States Environ-
mental Protection Agency, 2004). When there is low conﬁdence in
multiple major elements, the compounding of conservatism used to ad-
dress these uncertainties may lead to unrealistic and implausible risk
estimates (Burmaster and Anderson, 1994; Burmaster and Harris,
1993; Burmaster and Lehr, 1991; Burmaster and von Stackelburg,
1991; Cullen, 1994). If uncertainties are sufﬁciently large (i.e., the total
uncertainty factor (UF) is greater than 3000), EPA's IRIS program may
decide against developing a toxicity value.
2.2.2. Identiﬁcation of major elements
2.2.2.1. Toxicity assessment. The elements and their respective constitu-
ents that have been identiﬁed as being important to characterize conﬁ-
dence in toxicity values are provided in Table 3 for non-cancer
assessments and Table 4 for cancer assessments. It is important to
note that many aspects of these elements are interrelated. For example,
the availability of mode of action (MOA) information is important for
the identiﬁcation of the critical effect, the relevance of critical effect to
humans, and for the dose–response modeling. For the POD element, in-
formation frommultiple dose groups deﬁning the range and slope of the
dose–response curve is more likely to be available if the study quality is
adequate. These elements may differ, in part, from themore typical UFs,
which have the deﬁned purpose of producing a health-protective toxic-
ity value (United States Environmental Protection Agency, 2011).
The elements identiﬁed in Tables 3 and 4 are envisioned to be used
in a systematic manner within an assessment to enhance transparency
and to help the risk manager or user of a toxicity value to better under-
stand the overall conﬁdence in the value.
2.2.2.2. Conﬁrmation of toxicity assessment quality. Elements that are not
part of the toxicity assessment but that help conﬁrm that the toxicity as-
sessment is of high quality are also considered in this approach. These
elements are listed in Table 5 and are also discussed below as the pro-
posal to explicitly consider them as part of the discussion of conﬁdence
in the toxicity assessment is a novel part of this proposed approach.
2.2.2.2.1. Peer review. External peer reviews are increasingly being
used to evaluate the scientiﬁc basis of toxicity values. A high quality
peer review, conducted by a panel of appropriate experts, increases
the conﬁdence in decisions, especially if a completed independent anal-
ysis demonstrates that all substantive peer review comments were ad-
equately addressed. External peer review helps to ensure that the most
relevant and appropriate scientiﬁc thinking is incorporated and subse-
quently leads to better decision-making. The most rigorous external
panel reviews, which seek consensus, typically provide the highest con-
ﬁdence in the review and the resulting ﬁnal assessments. Although less
robust than an external peer review panel, peer input, and peer consul-
tation can contribute signiﬁcantly during the process of development of
a toxicity characterization (Meek et al., 2007).
2.2.2.2.2. Validation check. In some cases, the aggregate impact of the
assumptions and procedures used to address uncertainties in a toxicity
characterization may result in a toxicity value that is unrealistic. ByTable 5
Elements for conﬁrmation of toxicity assessment.
Element Description for high conﬁdence
Peer review An external independent peer review was conducted
including opportunities for public comment, written peer
review report available, and the Agency responded
appropriately to peer review and public comments.
Validation The agency has evaluated whether the ﬁnal toxicity values are
realistic and plausible based on available information.
Toxicity value
comparison
Relevant values from high quality, peer reviewed sources, are
within three-fold of each other (see Section 2.2.2.2.3).
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conservatism that may exist in each default UF is compounded as the
upper bounds on each of the factors is used in the calculation
(Burmaster and Harris, 1993; Burmaster and Lehr, 1991; Cullen, 1994).
One example of a validation check for a cancer toxicity value would
be to calculate the expected response in the reference population based
on a central estimate rather than upper percentile estimate of the unit
risk factor or slope factor using the estimated exposure.5 The estimated
incidence in a population based on this central estimate can then be
comparedwith the reported incidence in a registry such as The Surveil-
lance, Epidemiology, and End Results Program of the National Cancer
Institute (2015). If, for example, the estimated incidence of the cancer
using the central estimate of the toxicity value and reasonable estimates
of exposure is substantially higher than all reported cancers of that type,
irrespective of established risk factors, this suggests that the toxicity
value has been overestimated. One can then also judge if the inherent
conservatism in the upper percentile estimate is appropriate. Other ex-
amples of validation checks are provided in approaches described by
TCEQ (2012).
To conduct a validation check, toxicity values could also be com-
pared to high quality epidemiology data to evaluate whether they are
biologically plausible (Hays et al., 2007; LaKind et al., 2008). Criteria
from the latest reference concentration/dose derivation guidance docu-
ments on the differential toxicity of chemical classes or isomers (United
States Environmental Protection Agency, 1994; United States Environ-
mental Protection Agency, 2002), as well as scientiﬁc judgment should
be used. The availability of this comparative data allows risk managers
to tie the existing toxicity values to known human exposures via a risk
characterization. A validation check enables decisions in which greater
conﬁdence can be placed.
2.2.2.2.3. Toxicity value comparison. Side-by-side comparison of rele-
vant toxicity values fromother expert bodies can augment or reduce the
conﬁdence of a newly derived or revised toxicity value. Such compari-
sons may indicate the need to look at the underlying database for a
chemical, and in particular the time elapsed since completion of an eval-
uation. The appropriate time frame may depend on when a key study
was made available and whether or not previous evaluations were
able to consider this information. Section 2.1, as well as discussions in
Dourson and Lu (1995) and Beck et al. (2013), provides a discussion
of a comparison of toxicity values derived from different organizations.
For this approach, if the relevant toxicity values from different organiza-
tions agree, for instance, within three-fold of each other, this can signify
a degree of independent veriﬁcation and risk managers can use the
resulting toxicity values with higher conﬁdence. If relevant toxicity
values disagree beyond 10-fold of each other, the reasons for the differ-
ence should be investigated. There may be a logical explanation for the
differences (e.g., differences in critical study or choice of dose–response
model). Riskmanagersmay choose to use the toxicity value that has the
strongest scientiﬁc basis or the value that is most consistent with their
problem formulation, or alternatively they may choose to use the
most conservative toxicity value as a matter of policy. Whatever is se-
lected, the supporting justiﬁcation should be noted to promote
transparency.
2.2.3. Quantitative evaluation of major elements
To increase transparency and enhance understanding of uncertainty
in a toxicity value, quantitative scoring can be used to illustrate and
communicate both the direction and magnitude of conﬁdence for each
element. A numerical scale from1 to 5 is assigned,with 1 being low con-
ﬁdence and 5 being high conﬁdence. Alternatively, a qualitative ranking
system of low, medium, or high conﬁdence could be used depending on
the speciﬁc problem formulation or preferred communication style. For5 This may be applicable for rare or relatively rare tumors only.example, a risk manager with an engineering background may prefer a
quantitative scale whereas other managers might prefer a qualitative
system.
The scales shown in Figs. 1 and 2 were designed to reﬂect the same
“direction,” that is, low always means low conﬁdence (and therefore
high uncertainty). One advantage of using this scoring system is that it
can highlight those areas where additional research may improve the
conﬁdence in the toxicity value. For example, those elements or constit-
uents scored as low conﬁdence in a chemical-speciﬁc toxicity assess-
ment would be candidates for speciﬁc research aimed at reducing
uncertainties in these components of the toxicity value.
An alternative outcome for low conﬁdence assessments has been
suggested for situations where the available data are not sufﬁcient for
a quantitative screening assessment. In these cases, the assessment de-
faults to a qualitative evaluation as described by the National Research
Council (2009) and Meek et al. (2013).
For a scoring system to be used, it is vital that criteria for scoring and/
or ranking of the elements are adequately and transparently deﬁned.
Scoring is envisioned to be conducted based on professional judgment
and will be more robust if a team of evaluators participates in scoring
and consensus is sought for each score. Ideally both the author(s) and
the peer reviewer(s) of the toxicity assessment would participate in
scoring the elements; for example the authors could provide their
score to peer reviewers, who would independently score the elements.
To foster transparency, the magnitude of conﬁdence for each element
and the corresponding rationale should be compiled into a narrative
or a data table. The Supplemental material discusses the basis for scor-
ing each of the elements listed in Tables 3, 4, and 5. Presented in tabular
form, the Supplemental material provides the following basic
information:
1. The name of the element organized into hazard and dose–response
for non-cancer (Supplemental materials A), cancer (Supplemental
materials B), and elements that help conﬁrm the toxicity value (Sup-
plemental material C);
2. The magnitude of the conﬁdence using scaling from 1 to 5 or a qual-
itative ranking systemof low,medium, or high conﬁdence (high con-
ﬁdence is represented by a higher number, which is analogous to low
uncertainty);
3. Implications for risk characterization, which explains the basis of its
magnitude of conﬁdence scoring;
4. Conﬁdence in the element which explain the impact of this element
on the accuracy, precision, predictiveness, and/or health protective-
ness of the value (health protective meaning greater likelihood of
overestimating risk); and
5. Relevant literature references.
The tabular formats presented in the Supplemental material can be
readily adapted for use as templates for summarizing conﬁdence in
each key element. As an example, Table 6 illustrates the criteria for de-
ﬁning the conﬁdence (numerically 1–5 or from low to high) in the
dataset for the element “relevance of the critical effect.”
2.2.4. Graphical representation
The results of the scoring of elements can be displayed graphically to
provide a clear and transparent visual on the strength of the available
data and analyses for the chemical (and resulting level of conﬁdence
in the toxicity value). Including both a narrative and graphical represen-
tationwill be appropriate given themultiple stakeholders. The goal is to
provide an overall picture of data availability and quality, and to graph-
ically represent conﬁdence in the available data and analyses (National
Research Council, 2013).
Figs. 1 and 2 are examples of a graphical representation that were
identiﬁed by workshop participants as a potentially useful depiction of
conﬁdence scoring based on elements. The chronic inhalation reference
concentration (RfC) for carbon tetrachloride (CCl4) was used as an ex-
ample chemical for Fig. 1 (United States Environmental Protection
Fig. 1. Conﬁdence scoring for inhalation reference concentration (RfC) for carbon tetrachloride (CCl4).
116 N.B. Beck et al. / Environment International 89–90 (2016) 110–128Agency, 2010b). For comparison, the inhalation reference value (ReV)
for 4-vinylcyclohexene (4-VCH) is shown in Fig. 2 (Texas Commission
on Environmental Quality, 2011). Three of the elements are not repre-
sented in the overall conﬁdence scoring of low to high but rather are
scored as having been completed (+, ++, or +++) or not completed
(−). The completed elements have been scoredwith either one or three
plus marks to indicate the judgment regarding the conﬁdence inFig. 2. Conﬁdence scoring for inhalation referencethe approach taken, consistent with the descriptions in Supplemental
material C.
Figs. 3 and 4 present this same information in a different format. This
approach places each evaluated element in a different colored and tex-
tured box with a qualitative scale (low, medium, high or not evaluated)
to showwhere it falls on the conﬁdence scale. In this case, the boxes in-
clude all the elements and factors that affect the toxicity assessment.value (ReV) for 4-vinylcyclohexene (4-VCH).
Table 6
Hazard identiﬁcation: relevance of critical effect.
Conﬁdence scale and
basis for scoring
1 = Low: critical effect identiﬁed in animal studies is
only assumed to be relevant to humans; MOA is not
known for the critical effect.
2–3 =Medium: the critical effect appears to be relevant
to humans (e.g. a biological basis exists although there
is no direct evidence). MOA is known for the critical
effect and possibly relevant to humans; or possibly
known and probably relevant to humans.
4–5 = High: the critical effect is based on human
experience; the critical effect observed in animal studies
is appropriate and matches observed human
experience; MOA is well understood so critical effect is
related or may be related to human ﬁndings.
Implication The EPA and IPCS mode of action/human relevance
frameworks are well supported internationally. Critical
effects warranting a higher conﬁdence result in risk
management decisions that have a ﬁrmer foundation.
References (Boobis et al., 2006; Boobis et al., 2008; United States
Environmental Protection Agency, 2002)
Table 7
Conﬁdence scoring for the inhalation RfC for CCl4.
Element Score
(1–5)
Basis
Database
completeness
3
Medium
Developmental study in different species and
multigenerational study lacking (conﬁdence from
United States Environmental Protection Agency
(2010b) was medium)
Systematic review 1
Low
At the time of this assessment, IRIS did not employ
a systematic procedure for data gathering,
analysis and internal review
Key study quality 5
High
The chosen study is well done and can be used
without restriction (conﬁdence from United
States Environmental Protection Agency (2010b)
was high)
Critical effect 4
High
Studies are sufﬁcient to determine the critical
effect with conﬁdence; fatty change in liver is
moderate severity
Relevance of
critical effect
5
High
The critical effect of liver toxicity is appropriate to
use for extrapolation to humans. Extrapolation
seems reasonable based on knowledge of MOA,
data from other experimental animal species, and
human epidemiology data. Critical effect matches
human experience
Point of departure
(POD)
5
High
A lower limit on the BMD was used as the POD.
Multiple dose groups
Human equivalent
POD (PODHEC)
4
High
HEC and duration adjustments were derived using
a PBPK model
Sensitive
populations
3
Medium
Available lifestage information does not suggest
increased childhood susceptibility
Peer review +++
High
The external peer review seemed adequate and
EPA appeared to take comments into
consideration
Validation – Not conducted
Toxicity value
comparison
– Not conducted
117N.B. Beck et al. / Environment International 89–90 (2016) 110–128Tabular presentations of conﬁdence scoring are also useful as com-
munication tools. Tables 7 and 8 show conﬁdence scoring of elements
in tabular form for CCl4 and 4-VCH, respectively. An advantage of a tab-
ular presentation is that it allows explanation of the scoring to be in-
cluded in the table.
All the examples of graphical representations attempt to display the
conﬁdence in individual elements of the toxicity assessments such that
the overall conﬁdence in the assessment can be captured in a single ﬁg-
ure. Other types of plots are possible and could even be preferred de-
pending on the situation, users and intended audiences. Regardless of
the speciﬁc format, the goal is a result that portrays a relative picture
of the conﬁdence (or overall level of uncertainty) in the toxicity value.Fig. 3. Conﬁdence scoring for inhalation RfC for CCl4.
Fig. 4. Conﬁdence scoring for inhalation ReV for 4-VCH.
Table 8
Conﬁdence scoring for the inhalation ReV for 4-VCH.
Element Score
(1–5)
Basis
Database
completeness
3
Medium
A subchronic inhalation study was available in
two species. Inhalation developmental study and
multigenerational inhalation study lacking. An
oral two generation reproductive/developmental
study in mice showed no effects on reproductive
function. (Conﬁdence from TCEQ (2011) was
medium).
Systematic review 1
Low
At the time of this assessment TCEQ did not
employ a systematic procedure for data gathering,
analysis, and internal review.
Key study quality 3
Medium
The chosen study was conducted using GLP in rats
and mice, although only10 animals/sex were
evaluated. (Conﬁdence from TCEQ (2011) was
medium).
Critical effect 2
Medium
Studies are sufﬁcient to determine the critical
effect with conﬁdence. Three concentrations were
tested and multiple endpoints evaluated. The
following critical effects occurred at the highest
concentration: ovarian atrophy and mortality
(severe effects) and lethargy/tremor (moderate
effects).
Relevance of
critical effect
1
Low
Mice are extremely sensitive for ovarian atrophy
because they produce more reactive metabolite
than humans. However, since it is possible that
humans produce the reactive metabolite, a default
assumption was made that ovarian atrophy may
occur in humans. The MOA for tremor/lethargy is
not known, so it was assumed these effects were
relevant to humans.
Point of departure
(POD)
2
Medium
BMC modeling was not conducted because
adverse effects only occurred at the highest
concentration. A NOAEL and a LOAEL were
identiﬁed.
Human equivalent
POD (PODHEC)
3
Medium
Default duration adjustments and
animal-to-human adjustments were conducted.
Sensitive
populations
1
Low
Lifestage information was not available to indicate
sensitive populations exist.
Peer review ++
Medium
Peer input, a 90-day comment period, and
comments were addressed.
Validation – Not conducted (data are not available to conduct a
reality check).
Toxicity value
comparison
– Not conducted (chronic inhalation values from
other sources were not available).
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comparisons of uncertainty across different chemical toxicity values
could be made more easily. For example, this approach facilitates
rapid visual comparison of the conﬁdence scoring in Fig. 3 for CCl4
(United States Environmental Protection Agency, 2010b) to the conﬁ-
dence scoring for 4-VCH (Texas Commission on Environmental
Quality, 2011) in Fig. 4.
Irrespective of the approach used, it is important that the conﬁ-
dence in the key assumptions used in deriving a toxicity value, and
the approaches employed to address uncertainties, are described
and transparently communicated. The TCEQ has used the tools de-
scribed in this approach to communicate the conﬁdence in the toxic-
ity characterizations for hexamethylenediamine (Myers and Grant,
2015; Texas Commission on Environmental Quality, 2015b) and
diethylamine (Grant et al., 2015; Texas Commission on
Environmental Quality, 2015a). It is also important that any chosen
graphic or tabular representation be tested with various user groups
(e.g., by targeted in-depth interviews or focus groups) that would in-
clude risk assessors, decision-makers, risk communicators, and
stakeholders/general public. Focus groups are one approach that
can be used to test comprehension of the concepts and conclusions
and improve on graphical representations. A number of other mes-
sage testing technique tools are also available (Budescu et al.,
2009; Ibrekk and Morgan, 1987; Lipkus, 2007; National ResearchCouncil, 2013). Effective communication tools will enable risk man-
agers to make more informed decisions.
2.3. Approach 3: presenting toxicological information visually in the context
of alternative values and exposure levels
This section provides a visual approach for cancer and non-cancer
toxicity values that attempts to help contextualize relationships be-
tween doses that produce adverse effects, toxicity values, andmeasured
or estimated actual human exposures. As it is difﬁcult for one single
graphic to capture all the necessary information, a series of ﬁgures
that will capture different types of information is proposed. The series
of ﬁgures can be used to convey the relationships between toxicolog-
ic/epidemiologic observations, uncertainty, commonly used riskmetrics
(e.g., RfDs) andmeasured exposures or estimates of potential exposure.
In addition, this approach facilitates graphical depiction of information
on guidance values developed by other organizations (e.g., see discus-
sion of the ITER database in Section 2.1), which gives the audience an
understanding of how the same underlying database can yield different
results. While it is recognized that IRIS evaluations, and other similar
hazard-only assessments, do not incorporate exposure information,
the proposed ﬁgures allow for inclusion of this information, which can
be important for perspective, where appropriate. Depending on the sce-
nario, intake levels or ambient environmental levels could also be pre-
sented. Including this information gives stakeholders, risk managers,
and others the opportunity to put toxicity values in the context of expo-
sure, which may be valuable for presentations outside of the actual IRIS
or toxicity value documentation andmay aidwith decisions that involve
choices among diverse toxicity values.
This approach builds upon the communication model developed for
the biomonitoring equivalents (BEs) (Hays et al., 2007; LaKind et al.,
2008). The BE is deﬁned as the biomonitoring levels of a speciﬁc chem-
ical in blood, urine, or other human biological media or tissues that is
consistent with the daily exposure to a level of a substance equal to its
toxicity value, such as an oral RfD or a POD. This approach was devel-
oped for use by risk assessors as these graphics should be readily under-
standable to this audience. Risk assessors can then use the ﬁgures as
tools to explain the data, its derivation, and its context to risk managers
whoneed to be cognizant of these factors. The graphical communication
approach for BEs (LaKind et al., 2008) was adapted to help visually con-
vey components of uncertainty in hazard assessments and how risk
management decisions are affected by uncertainty.
The basic components of a visual aid developed to convey the impor-
tant relationships discussed above are described in this section using a
non-cancer example. In describing relationships, it may appear that
each toxicity value is known with certainty and represents a bright
line between safe and unsafe levels. However, although toxicity value
point estimates are often used in this manner, it is important to note
that the true deﬁnition, at least for an IRIS value, includes a range of
values that could span an order of magnitude of uncertainty (United
States Environmental Protection Agency, 2011). The approach includes
multiple ﬁgures, each conveying different important aspects related to
the toxicity value, as described below. It is envisioned that for a web-
based platform this approach will utilize pop-up boxes and scroll-over
techniques to help make the information accessible. It is also important
to note that some graphical representations are not drawn to scale as
the general public likely lacks familiarity with a logarithmic scale, creat-
ing a challenge in cases where values differ by orders of magnitude.
Fig. 5 presents the basic graphic for a non-cancer toxicity value,
which is a box diagram with upper and lower arrows. The two-
headed arrow graphic itself is meant to highlight the fact that possible
intakes or exposures could extend above or below the ranges shown
in the diagram (i.e., exposures (doses) could theoretically range from
the upper tail of a distribution to exposures that are very low and corre-
spond to extremely low potential for any response). The shading, from
darker at the top to lighter at the bottom, represents higher to lower
Fig. 5. Basic visual aid for presenting a non-cancer reference value.
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speciﬁc chemical using the BMD methodology (United States Environ-
mental Protection Agency, 2012) or a NOAEL, and a corresponding ref-
erence value (a toxicity value such as an RfD or RfC) for non-cancer
effects. The composite UF is depicted by the dashed line from the PODFig. 6. Derivation of oral RfD for CCto the reference value. For cancer endpoints, risk speciﬁc doses based
on tumor responses at human equivalent doses (oral) or concentrations
(inhalation) could be presented. In a web-based ﬁgure, scroll-over
boxes could present more detailed information about each element in
the ﬁgure. This is shown by the explanatory boxes in Fig. 5.l4 data from US EPA (2010b).
Fig. 7. Derivation of oral RfD for CCl4 data from RIVM (Baars et al., 2001).
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CCl4 IRIS assessment for oral non-cancer effects, including the POD
(3.9 mg/kg-day), the composite UF (1000), and the resulting RfD
value (0.004 mg/kg-day) (United States Environmental Protection
Agency, 2010b). Fig. 7 uses the same graphical template to present the
results of the CCl4 assessment from the Netherland's National Institute
for Public Health and the Environment (RIVM) (Baars et al., 2001). In
Fig. 8, using the non-cancer inhalation toxicity evaluations for carbon
tetrachloride, a comparison of multiple alternative reference values is
presented. The arrow ﬁgure shows the values for RIVM, ATSDR, and
EPA, and the associated pop-up box shows further details including
the PODs and UFs for each of the derivations from each agency. While
color coding makes this ﬁgure easier to interpret, it is recognized that
this level of detail may be of great interest a risk assessor as compared
to a risk manager. Figs. 9 and 10 show how similar graphics could be
used to depict cancer endpoints.
This graphic can also be used to portray a reference value in the con-
text of known or estimated exposure information or BEs. Fig. 11 illus-
trates these points. By comparing the toxicity value with the range of
estimated human exposures and/or the BE with blood or serum levels
of chemicals from the Centers for Disease Control and Prevention
(CDC) National Exposure Report on Human Exposure to Environmental
Chemicals (Centers for Disease Control and Prevention, 2014). A graphic
such as this would provide context to allow understanding of how close
exposures are to the reference toxicity value, which generally contains
large uncertainties, and to the POD which is based on actual toxicity
testing data. The graphic can also informwhether the BE is close to typ-
ical steady-state population blood or urine level ranges for environmen-
tal chemicals of interest. Comparing the PODs and reference value levels
for multiple compounds to exposures or population blood or urine
levels can help inform prioritization of chemicals for further evaluation
of uncertainties where margins of exposure are relatively small.
While graphics containing the information in the ﬁgures described
above can be part of a printed document, additional value for educational
purposes can be derived by making them “active” rather than “passive”
ﬁgures. Using “mouse over” electronic ﬁgures, deﬁnitions, furtherinformation, and even data tables and other ﬁgures can be linked to the
above ﬁgures and provided in real time as needed. This approach is likely
to have signiﬁcant value to risk managers or members of the public who
are not aswell acquaintedwith the risk assessment process, its uncertain-
ty and variability, and its role in the risk management process. As with
other approaches, the graphics should be testedwith various user groups
to ensure that the graphics are understood and have utility.2.4. Approach 4: depicting uncertainty and variability in individual
elements
Uncertainty and variability analysis in hazard and dose–response
should be described in the problem formulation step. This includes the
development of toxicity values such as RfDs and also for more recent
tiered assessment strategies designed to increase efﬁciencies in assess-
ment. These are frequently based on consideration of a much broader
range of datasets using margin of exposure (MOE) approaches.
For example, the World Health Organization/International Pro-
gramme on Chemical Safety framework on combined exposure to mul-
tiple chemicals includes problem formulation followed by stepwise
integrated and iterative consideration of both exposure and hazard in
MOE in several tiers of increasingly data-informed analyses
(International Programme on Chemical Safety, 2014). Its development
and application has illustrated the importance of “framing” quantitative
estimates of toxicity in the context of exposure, not only to characterize
their relative degree of conservatism and associated uncertainty, but
also to identify those parameters which have the greatest impact on
the toxicity value. This approach could provide a basis for sensitivity
analysis and efﬁcient and meaningful reﬁnement in higher tiers of any
risk evaluation that used the toxicity value (Meek et al., 2013).
There is a need, then, to increase transparency in distinguishing as-
pects of uncertainty and variability in existing approaches. This would
provide ameans of understanding the extent of conservatism in various
elements and would also provide a determination of the sensitivity of
the toxicity value to the various decisions made. This increased
Fig. 8. Figure showing multiple comparison values for CCl4 noncancer inhalation data (Agency for Toxic Substances and Disease Registry, 2005; Baars et al., 2001; United States Environ-
mental Protection Agency, 2010b).
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the assessment that have the most impact on the outcome.
2.4.1. Using the templates for communicating uncertainty and variability
In this section, a template for communicating uncertainty versus
variability in toxicity value derivation for a case example is presentedFig. 9. Basic visual aid for presein Table 9. The information in this table is presented in the order of con-
duct of important elements/decision points in the dose–response com-
ponent of the toxicity value development. Information in this table
contributes to the prioritization of factors that are the most important
determinants of outcome, a potential template for which is presented
in Table 10. The implications of increased transparency in addressingnting a cancer value (oral).
Fig. 10. Derivation of oral cancer value for CCl4 data from US EPA (2010b).
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discussion.
A ﬁrst important goal to ensuring a transparent summary of the
characterization of dose–response gives a distillation of the dose–re-
sponse assessment down to key elements within the existing frame-
work. Typically, dose–response assessments include the following
steps: (1) critical effect endpoint data set selection; (2) dose–responseFig. 11.Comparison of the CCl4 RfC data fromUS EPA (2010b) to background levels fromATSDR
to this RfC to empirical human biomonitoring data from Centers for Disease Control and Prevemodel selection and POD determination; (3) extrapolation to a human
equivalent dose POD (PODHED) (e.g., duration adjustments, physiologi-
cally based pharmacokinetic (PBPK) modeling, allometric scaling);
and (4) low-dose extrapolation (e.g., uncertainty factor selection, MOE
designation, linear assumption). Some steps can be expanded to show
additional detail/decisions. For example, dose–response modeling also
includes embedded decisions for the selection of an appropriate(2005) and comparison of the biomonitoring equivalent value data in blood corresponding
ntion (2014).
Table 9
Summary table showing uncertainty and variability in decisions made in an oral noncancer assessment (acrylamide).
1.  Decision 
point
2.  Range of optionsa
Fraction of central tendency value 
(indicated by dashed line for quantitative 
decision points)
3.  Range reflects uncertainty 
or variability
4.  Basis for normalizing 
values (e.g., central 
tendency or highest 
confidence value)
5.  Decided 
option
6.  Confidence in 
decision (science–or 
policy–based)
Data 
set/endpoint 
selectionb
Variation in the effective 
chronic NOAEL values 
(minimum and maximum values 
calculated from EPA Table 5–1)c
Mean effective chronic 
NOAEL value across 
candidate studies (6.1 
mg/kg–day, based on 
data provided in EPA 
Table 5–1)
NOAEL for 
peripheral nerve 
effects (0.5 
mg/kg–day; 
Johnson et al., 
1986)
Medium/High 
confidence in key study.  
Selection of a sensitive 
endpoint and study 
reflects a policy 
decision to be 
protective
Causative agent 
determination 
(MOA)b
1) Neurotoxicity is attributed to acrylamide
2) Neurotoxicity is attributed to glycidamide
Uncertainty in MOA regarding 
causative agent
NA Neurotoxicity is 
attributed to 
acrylamide
Not explicitly stated by 
EPA
Dose–response 
model selectionb
Variation in POD across models, 
based on minimum (1.2 mg/kg–
day) and maximum (1.8 mg/kg–
day) for alternative BMD values
Mean POD of acceptable 
models (1.4 mg/kg–day; 
EPA Table C–2)
Log–logistic model 
(1.2 mg/kg–day; 
EPA Table C–2)
High confidence (EPA 
Section 5.3.1.3).
Selecting the best 
fitting model reflects a 
science–based decision 
to be predictive
Confidence limit 
selection
Uncertainty in model 
parameters for log–logistic 
model, based on BMDL10 (0.57 
mg/kg–day) and BMD10 (1.2 
mg/kg–day) from EPA Table C–2
POD = BMD (1.2 mg/kg–
day; central tendency)
POD = BMDL (0.6 
mg/kg–day; 95% 
lower confidence 
limit)
Not explicitly stated by 
EPA, however selecting 
lower confidence limit 
reflects a policy–based 
decision to be 
protective
Benchmark 
response rate 
selection
Uncertainty in POD response, 
based on range defined by the 
BMDL01 (0.05 mg/kg–day) and 
BMDL10 (0.57 mg/kg–day) from 
EPA Table 5–3
BMR = 10% (BMDL10 = 
0.57 mg/kg–day) for the 
default response rate for 
dichotomous data
BMR = 5% 
(BMDL05 = 0.27 
mg/kg–day)
Not explicitly stated by 
EPA, however selecting 
a BMR value (5%) that is 
below the default value 
(10%) appears to reflect 
a policy–based decision 
to be protective
Interspecies 
extrapolation 
(rat dose:HED)b
Variation across measured/ 
estimated adduct rates in rats 
and humans, based on the 
range rat dose:HED ratios for 
acrylamide (0.035–16.4) from 
EPA Table 5–6
Based on assumption of 
equivalent dose (i.e.,  rat 
dose:HED = 1)
Based on relative 
rates of AAVal 
formation in rats 
(27.4 uM–hr per 
mg) and humans 
(140.1 uM–hr per 
mg) the rat 
dose:HED = 5.1
Not explicitly stated by 
EPA
Interspecies 
variation (UFa)
Variation across species, based 
on a default range for 
toxicodynamics (3–fold in each 
direction, or 0.33–3)
UFa=1 (assume humans 
and rats are equally 
sensitive)
3 (assume that 
humans are 3x 
more sensitive 
than rats based on 
toxicodynamic 
factors)
Not explicitly stated by 
EPA, however selecting 
a value greater than 1 
reflects a policy 
decision to be 
protective
Intraspecies 
variation (UFh)
Variation across individuals, 
based on a default range of for 
toxicokinetics and 
toxicodynamics (10–fold in each 
direction, or 0.1–10)
UFh=1 (for average 
individual)
10 (assume some 
individuals are 10x 
more sensitive)
Not explicitly stated by 
EPA, however selecting 
avalue greater than 1 
reflects a policy 
decision to be 
protective
Duration 
extrapolation 
(UFs); LOAEL–to–
NOAEL 
extrapolation 
(UFl); Database 
uncertainty 
(UFd)
Uncertainty in additional 
factors, based on default range 
(1–10)
UFs=1; UFl=1; UFd=1 1 for each (key 
study is chronic; 
BMD methods 
used; database is 
complete)
Medium/High 
confidence places in the 
toxicity database
Results Central tendency 
value = 3 mg/kg–day
RfD = 0.002 
mg/kg–day
Medium/high 
confidence in RfD
aThe shading gradient of the lines indicates the direction of higher or lower conservatism.Values in thedarkblue region result in lowerRfDs than the light blue region. The length of the line
in this ﬁgure provides a relative indicator of the range of possible values for selection in this step in the assessment. The range reﬂects the minimum andmaximum value, as scaled to the
value contained in Column 4. A contrast gradient indicates direction corresponding to amore or less conservative result (darker shading indicates amore conservative value; lighter shad-
ing indicates a less conservative value). Finally, a marker (red triangle) is placed on the line to depict the value selected by the assessor, in this case EPA (United States Environmental
Protection Agency, 2010a).
bDecision points that are impacted by MOA conclusions are designated with an “*”. Adopting of a different MOA conclusion may yield alternative results for these decision points.
cRange of effective chronic NOAEL values for each endpoint: neurotoxicity (0.02–25 mg/kg-day); reproductive (0.79–18.7 mg/kg-day); developmental (0.5–45 mg/kg-day). Effective
chronic NOAEL values reﬂect that application of default uncertainty factors of 10 each for use of a LOAEL and/or subchronic study for comparison purposes.
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Table 10
Summary of conﬁdence and importance of decisions made for the noncancer oral assessment (acrylamide).
1. Importance of decision to assessment versus confidence in 
decisionb 2. Confidence not specified in EPA
(2010)
3. Prioritization of data needs (section 
discussed)
High confidence
Medium 
confidence Low confidence
Im
po
rt
an
ce
 o
f D
ec
is
io
n 
to
A
ss
es
sm
en
ta
H
ig
h
Causative agent determination (MOA)
Interspecies extrapolation (rat dose:HED)
Intraspecies variation (UFh)
1) Causative agent determinationc (EPA 
Section 4.7.3.1.4)
2) Data set (EPA Section 5.3.1.1)
3) Interspecies extrapolation (EPA Section 
5.3.1.4)
4) Intraspecies variation (not identified by 
EPA)
M
ed
iu
m
Benchmark responserate selection
Interspecies variation (UFa)
Addition uncertainty factors (UFs, UFl, 
UFd)
None identified by EPA
Lo
w Dose-response
model selection Confidence limit selection Not applicable
Data set/endpoint selection
aRelative importance of decision to the assessment characterized using the range of options deﬁned in Table 10, Column 2: high (N10-fold range deﬁned bymin andmax);medium (3- to
10-fold range); low (b3-fold range).
bConﬁdence based on the designation in the last column of Table 9.
cConsidered high since this decision impacts multiple steps in the assessment.Note: Shaded region of the table can be used to identify priority data needs for additional research/reﬁned
assessment.
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dence limit (e.g., 95%, 50%, 5%).
A second important goal is to provide a simple way to describe the
decisions associated with each of the key steps. This is essential for un-
derstanding the impact of each decision on the ﬁnal toxicity value. For
each step in the assessment it is important to:
(1) Identify the value selected and where the selected value or op-
tion falls within the range of possible options (e.g., range of
values for quantitative steps; range of plausible options for qual-
itative steps);
(2) Specify if the range of options or values for the step reﬂects un-
certainty or variability;
(3) Provide a brief explanation of the rationale for the selection, indi-
cating if the selection is based principally on policy
(e.g., incorporating conservatism to be additionally protective),
on science, or on professional judgment. Also considered is
whether the decision is intended to be protective or predictive
of human health (e.g., does it represent the most conservative
vs. most certain option or value);
(4) Specify the degree of conﬁdence in the selection made; and
(5) Identify critical data needs that could be used to reduce uncer-
tainty and/or increase conﬁdence in the selection, and to priori-
tize these needs to the extent possible.
An example summary table is presented for the acrylamide oral
noncancer assessment (United States Environmental Protection Agen-
cy, 2010a) in Table 9, with one row for each step in the assessment.
The contents of each row are contingent upon the decisions made in
previous steps (e.g., the options for causative agent in row 2 are speciﬁc
for neurotoxicity, since neurotoxicity reﬂects the endpoint selected in
row 1, and therefore do not reﬂect options for all endpoints). Note
that the data in this table are provided simply as an example for a spe-
ciﬁc chemical on how to present such information, and the selected
values and options do not reﬂect any decisions endorsed by the co-
authors of this paper. Where the data were available, the table reﬂects
what was inferred or implicitly stated in the EPA documentation for
the acrylamide ﬁle. The table is intended to serve as a ﬂexible tool;
other chemicals and assessments could contain different elements.
In Table 9, Column 1 contains a description of the elements in the as-
sessment. Column 2 shows a list of the plausible options for qualitativedecision points (e.g., MOA) and for quantitative decision points
(i.e., those resulting in the selection of a numerical value). A ﬁgure is
provided inwhich a line depicts the range of possible values normalized
to a central tendency value which is the most predictive/highest conﬁ-
dence value (i.e., the value deﬁned in Column 4), shown on a log scale.
Column 3 contains a description for the range of options for selec-
tion, identifying speciﬁcally if the range reﬂects uncertainty or variabil-
ity in the parameter, and identifying the source of the values
(e.g., reference to another table). Column 4 identiﬁes the central ten-
dency used to normalize the range of options (e.g., mean or median)
used to create the ﬁgures in column 2. For example, if the mean value
is selected for the central tendency estimate, values for options are
then expressed as a fraction of the mean for depiction in the ﬁgure. Col-
umn 5 contains the option or value selected by the risk assessor. For
quantitative decisions, this is the value depicted by the red triangle
marker shown in Column 2.
Column 6 contains a statement on the level of conﬁdence from the
risk assessor with respect to the decision made. This differs in focus
from the conﬁdence statements typically included in IRIS assessments.
For example, EPA's designation of “conﬁdence in the key study” is typical-
ly limited to a consideration of the study design (e.g., number animals,
number of dose groups, exposure duration, histopathology methods).
In contrast, “conﬁdence in the decision to rely upon this study for human
health risk assessment” needs to address additional considerations,
such as the appropriateness of the endpoint (i.e., relevance to human
health), factors related to whether the decision was made based on
highest conﬁdence values, or whether it incorporates conservatism as
a basis to be additionally protective (i.e., science policy). It is recognized
that some decisions are made with the intention of being “protective”
(e.g., uncertainty factor selection), while other decisions are made
with the intention of being “predictive” (e.g., extrapolation of dose
across species). To be useful, any statement of conﬁdence should be ac-
companied by a description of the speciﬁc intentions of the risk asses-
sors. Overall, an assessment should balance a level of predictiveness or
protectiveness that is appropriate for the decision being made. For pro-
tective decisions, the degree of conservatism introduced into the assess-
ment can be quantiﬁed by comparing the values in Columns 4 and 5,
which also corresponds to the deviations from a value of 1 for the red
marker in the ﬁgures in Column 2.
The last row of Table 9 provides three pieces of information:
(1) what result (in this case RfD) would be obtained if central tenden-
cy/highest conﬁdence values were used at each step in the assessment
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tained based on the decisions made by the assessor at each step; and
(3) an overall conﬁdence statement in the result based on a consider-
ation of the individual statements of conﬁdence. The difference between
the central tendency/highest conﬁdence (i.e., most predictive value)
and the derived value may be orders of magnitude. Footnotes can be
added to the table to indicate potential relationships between decision
points. For example, the choice of theMOA affects the decision for calcu-
lating the PODHED (selection of an appropriate internal dose), dose–Fig. 12. Example of exposure distribution for inhalation using hypothetical scenarios. A.
Hypothetical inhalation exposure distribution to carbon tetrachloride that is primarily
below the hazard range from the RfC of 100 μg/m3 to the POD of 5000 μg/m3. A small
proportion of exposure is higher than 100 μg/m3. PDF is the probability density function
of exposure. B. Hypothetical inhalation exposure distribution that is beginning to fall
within the 100 to 5000 μg/m3 hazard range. A small proportion of exposures is higher
than 1000 μg/m3 (i.e., the midpoint). PDF is the probability density function of exposure.
C. Hypothetical inhalation exposure distribution that is falling more within the 100 to
5000 μg/m3 hazard range. A small proportion of exposures is expected to be higher than
5000 μg/m3. PDF is the probability density function of exposure.response model selection (e.g., use of a biologically-based dose–re-
sponsemodel) and low-dose extrapolation (linear vs. nonlinear). In ad-
dition, footnotes can be provided to include additional details regarding
the basis for the calculations (e.g., effective chronic NOAEL values used
to populate the ﬁrst row of the table).
The information contained in Table 9 can be reorganized to help
identify priority data needs as shown in Table 10. In this table, the rela-
tive importance of each element/decision (as indicated by the magni-
tude of the range of options or values in Column 2 of Table 9) is used
to organize the decisions by row (high, medium, or low importance).
The conﬁdence in the decision (high, medium, or low) is expressed in
Column 1. Ideally, a conﬁdence statementwould bemade for each deci-
sion and would be available from the authors of the assessment. How-
ever, for the acrylamide example discussed here, conﬁdence
statements are not available for a number of decisions, and therefore
the decisions alone, without any clear conﬁdence designation, are in-
cluded in Column 2 of Table 10. Column 3 of Table 10 presents the pri-
oritization of data needs, which should be focused on decisions with
medium-to-high importance and also medium-to-low conﬁdence
(i.e., the shaded region of Table 10). For the acrylamide example, EPA
identiﬁed data needs for several decisions of high importance, but not
for intraspecies variation. Furthermore, data needs were not identiﬁed
for several decisions of medium importance, and EPA's discussion of
data needs is brieﬂy mentioned in several places in the document. Ide-
ally, the data needs discussion for toxicity values should be more com-
plete (e.g., to include consideration of medium importance items),
consolidated into a single section, and prioritized (e.g., numbered list
can then be included in the last column of Table 9).
To be used as a summary tool, the size of Table 9 would ideally be
limited to a single page, but thismay not always be possible, particularly
for complex assessment. This format may also be useful for comparing
assessments performed by other regulatory agencies, or across
chemicals. For example in Column 2, decisions made by different agen-
cies could be depicted using different coloredmarkers (e.g., red for EPA,
blue for ATSDR). In electronic or web-based format, user interactivity
could also be incorporated by allowing the user to slide these markers
(mouse click and hold) to alternative options and to see the impact on
the resulting toxicity value.
The example summary tables presented in this approach illustrate a
way to visually present the key information in a manner that facilitates
communication. In electronic form this format can be readily extended
to allow users to interact with the table by selecting alternative options
to allow stakeholders, including risk assessors and risk managers, to see
the impact that decision point changes have on the overall derived
value. The elements and the tool can be used to help communicate the
uncertainty and variation embedded within components of a complex
assessment,make comparisons across hazard assessments, and to prior-
itize data needs to guide future research efforts. Increasing transparen-
cy, to distinguish aspects of uncertainty and variability in existing
approaches as a basis to characterize the extent of conservatism in var-
ious elements, and to address sensitivity, should also be helpful to risk
managers and other decision-makers.
2.5. Approach 5: using the toxicity value uncertainty range in association
with an exposure assessment
This ﬁnal approach incorporates a range around the toxicity value to
use as an educational tool to help stakeholders and risk managers un-
derstand the transition from protective to predictive values in associa-
tion with an exposure assessment. Although the use of screening
exposure levels at hazardous waste clean-up sites based upon non-
cancer endpoints is now common, this was not the case in the past
(United States Environmental Protection Agency, 2015). In many
cases, cancer risks provided the primary driver in site decisions. In gen-
eral, cleanup levels based on linear no-threshold cancer slope factors or
unit toxicity values producemore stringent cleanup levels than do non-
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non-cancer toxicity values. Guidance on risk management decisions in-
dicated a preference for the lower end of the excess lifetime cancer risk
range (e.g., the 100-fold cancer risk range of 10−6 to 10−4) (United
States Environmental Protection Agency, 1989; United States Environ-
mental Protection Agency, 1991).
A commonmethod for conducting a non-cancer assessment uses the
hazard quotient (HQ) as a quantitative indicator of the magnitude of
ratio between the exposure to a chemical and the reference dose. The
HQ is the ratio of the exposure to the toxicity value (e.g., HQ = Expo-
sure/RfD or RfC). For screening level purposes, multiple exposures and
multiple toxicity values can be combined to determine a hazard index
(HI) (see Dourson et al. (2013) for discussion of use of such screening
level calculations aswell as higher tiered procedures for evaluatingmul-
tiple chemical exposures).When evaluating the HQ and HI, risk man-
agers generally apply a point value (i.e., an HQ= 1) as the criterion of
safety. Although EPA has deﬁned RfDs and RfCs as possessing “uncer-
tainty spanning perhaps an order of magnitude,” risk managers may
not be aware that application of a range of HQ or HI values (i.e., a “haz-
ard range”) may be an acceptable way to account for this uncertainty.
This lack of awarenessmay be due, in part, to the lack of communication
and transparency of the uncertainty inherent in the calculation of the
RfD or RfC. Consequently, non-cancer hazards have frequently been
evaluated and regulated with a bright line approach. Risk managers
would beneﬁt from an in-depth, transparent analysis of the imprecision
and uncertainty present in these hazard assessments; such an approach
was recommended by EPA in guidance to inform ecological assessments
(United States Environmental Protection Agency, 2001).
Risk managers also routinely contend with other situations where
riskmanagement decisions are driven by non-cancer endpoints. Explic-
itly incorporating consideration of uncertainties into risk management
tools has not been widely implemented due in part to the fact that the
phrase in the deﬁnition of the RfD/RfC, “with uncertainty spanning per-
haps an order of magnitude,” has not been well deﬁned (Felter and
Dourson, 1998). Managers often interpreted such RfD/RfC values cau-
tiously, and expressed concerns associated with exposures exceeding
a hazard quotient of unity. What is not readily appreciated is that the
process by which uncertainty is accounted for in the derivation of the
RfD/RfC is often already implicitly precautionary; the application of as-
sumptions and uncertainty factors provides an additional explicit mar-
gin of safety in response to each source of uncertainty (Dourson et al.,
1996; Dourson and Stara, 1983).
A collaborative Alliance for Risk Assessment (ARA) (Alliance for Risk
Assessment, 2013) project has developed an approach to identify a
range of uncertainty in non-cancer toxicity values (i.e., “the hazard
range”); this approach is similar to the approach used for cancer toxicity
values in management of waste sites. The identiﬁed “hazard range” is
based on readily available information from EPA and other public
sources (Alliance for RiskAssessment, 2013). The purpose of developing
an approach to identify a range of values from protective to predictive
for non-cancer effects was to support and encourage more thorough
consideration of the uncertainty present in the non-cancer and cancer
toxicity values. Knowledge of this uncertainty will allow risk managers
to make more informed risk management decisions. The educational
tool proposed is shown in Fig. 12a, b, and c. Further discussion of how
to use this tool, including deﬁnitions of the hazard range and the inter-
mediate point, is provided in Supplemental material D.
3. Discussion and conclusions
Typically, in programs such as IRIS and the ATSDR toxicological pro-
ﬁles program, currently available methods for deriving human health
toxicity values do not seek to provide accurate predictions of the popu-
lation response. Rather, estimations of “safe” dose are developed,
through use of assumptions and uncertainty factors, to be health protec-
tive. Unfortunately, it is common for users of these values to view themas precise and accurate predictors of risk. Furthermore, the nature of
available toxicological and epidemiological data always results in
some recognized, yet often undeﬁned, level of uncertainty in risk
estimates.
For screening hazardous waste sites, a highly conservative toxicity
value may be suitable because the risk manager may wish to be very
conﬁdent that a conclusion reached regarding no further action has
accounted for a limited degree of site characterization. However, for
prediction of actual human impacts, such as those performed by IRIS
and ATSDR in human health toxicity assessments, the use of a highly
conservative toxicity value built upon an aggregation of assumptions,
due to uncertainties, is unlikely to be accurate. The intended use of the
toxicity value should determine the appropriate level of conservatism
and this should be clearly communicated.
As chemical hazard and dose–response assessments increase in their
complexity and robustness, supporting documentation can easily grow
to several hundred pages in length. In 2011, the NRC, in commenting on
a draft IRIS assessment, noticed that longer documents tend to have
problems associated with transparency and clarity (National Research
Council, 2011). These assessments often contain assumptions and
methods to address uncertainties (e.g., pharmacokinetic and pharmaco-
dynamic components such as PBPKmodeling, dose–responsemodeling,
and regression analyses of epidemiology data) that remain a “black box”
to all but the most experienced of risk assessors. For this reason, it has
become increasingly challenging to present this information in clear
and concise manner to risk managers and decision-makers.
In hazard and risk assessment documents that support toxicity value
development, discussions of conﬁdence in the toxicity value are some-
times included. In the case of IRIS, the RfD and RfC conﬁdence sections
often contain minimal information and tend to focus on limitations in
study design, study reporting, or data gaps. Such a focus cannot accu-
rately convey the types (e.g., missing studies or data, differing interpre-
tations of the data, varying policy considerations, and divergent
methods and assumptions for extrapolation to humans) andmagnitude
of the uncertainty present in the ﬁnal toxicity values.
A number of approaches exist to describe the range of uncertainty in
a hazard or risk characterization. When presented clearly, the utility of
visually displaying key information on uncertainty and the range of tox-
icity values provides a general sense of the strength of the available data
and conﬁdence in the overall assessment. Information underlying
graphical displays can be further analyzed, when necessary, to more ef-
fectively communicate the range of uncertainty in these values. As
discussed by theNAS, themost appropriate approach to communicating
uncertainty depends on the speciﬁc circumstances (National Research
Council, 2013). Numeric, verbal and visual (graphic) approaches all
have strengths and weaknesses that must be considered and the deter-
mination of the best approach to communicate uncertainty should be
made on a case-by-case-basis depending on considerations including,
but not limited to, the phase of the decision-making process, the pur-
pose of the communication, the decision context and the audience
(National Research Council, 2013).While the literature ismixed regard-
ing whether transparency actually does increase trust, as noted previ-
ously, there is evidence that a lack of transparency can lead to
increased distrust (Frewer and Salter, 2002; Frewer and Salter, 2012).
It was with these thoughts in mind that we developed the approaches
discussed in this manuscript.
The ﬁve distinct approaches presented here for communicating un-
certainty in the toxicity characterization process could be applied inde-
pendently of each other. For instance, TCEQ has started implementing
Approach Two (deconstructing toxicity assessments) in some of their
support documents (Texas Commission on Environmental Quality,
2015a; Texas Commission on Environmental Quality, 2015b). While
the approaches share some of the same concepts and thoughts about
characterizing uncertainty and conﬁdence, they portray this informa-
tion slightly differently. Common elements in each of the approaches in-
clude speciﬁc information related to the critical decision points
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dence in these values. All of the approaches increase transparency to
better inform decision-makers, a challenging but highly important
goal. Clearly there is no single, unique, “right” way to communicate
this type of information; different approaches will likely appeal to dif-
ferent individuals, regardless of their level of expertise or understanding
of hazard assessment and dose–response. It is strongly recommended
that consideration be given to testing these approaches, through focus
groups or other empirical methods to determine which approaches
will work best for speciﬁc audiences and situations. We hope to include
empirical testing of some of the approaches in the next phase of our re-
search activities in this area. Ultimately, the approaches can help in-
crease the transparency and ability to understand many of the
available hazard assessments. Incorporation of one or more of the sug-
gested approaches into future hazard and dose–response assessments
will help to improve understanding and use of uncertainty information
by risk assessors, risk managers, and stakeholders.
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